Viewing
Publication|Articles|August 13, 2024

Digital Edition

  • Ophthalmology Times: August 2024
  • Volume 49
  • Issue 8

A clear path ahead

Current Fuchs endothelial corneal dystrophy treatments include implanted cultured human endothelial cells.

Fuchs endothelial corneal dystrophy (FECD) is a common corneal disease that affects 4% to 7% of people in the US.1 FECD is a progressive dysfunction of the corneal endothelium characterized by abnormal endothelial morphology (pleomorphism and polymegethism) with an accumulation of guttae and excrescences on the Descemet membrane. Early disease is not typically symptomatic. Corneal edema occurs as the condition progresses, and patients may notice blurry vision, often more severe upon awakening.